

APELLIS PHARMACEUTICALS, INC.
COMPLIANCE COMMITTEE CHARTER

Adopted by the Board of Directors on March 29, 2023

A. Purpose

The purpose of the Compliance Committee (the “Compliance Committee”) of the Board of Directors (the “Board”) of Apellis Pharmaceuticals, Inc. (the “Company”) is to assist the Board with oversight of the Company’s healthcare compliance program by overseeing, evaluating and monitoring the Company’s compliance policies, standards, procedures, systems and initiatives as well as the Company’s information technology systems dedicated to quality, regulatory and commercial compliance.

B. Structure and Membership

1. Number. The Compliance Committee shall consist of at least three members of the Board.
2. Chair. Unless the Board elects a Chair of the Compliance Committee, the Compliance Committee shall elect a Chair by majority vote.
3. Compensation. The compensation of Compliance Committee members shall be as determined by the Board.
4. Selection and Removal. Members of the Compliance Committee shall be appointed by the Board, upon the recommendation of the Nominating and Corporate Governance Committee. The Board may remove members of the Compliance Committee from such committee, with or without cause.

C. Authority and Responsibilities

The Compliance Committee shall discharge its responsibilities and shall assess the information provided to it by the Company’s legal and compliance personnel, executive management and others, in accordance with its business judgment.

The Compliance Committee will provide oversight and strategic direction with respect to the Company’s healthcare compliance and ethics program, the scope of which includes the matters listed in Exhibit A (“Compliance Program”). The Compliance Committee will periodically assess the Compliance Program, provide recommendations and direction to executive management with respect to the Compliance Program, and apprise the Board of Directors of significant issues arising from the Compliance Program as needed.

Specifically, the Compliance Committee’s responsibilities are to:

1. Review the implementation of the Compliance Program, including policies, standards, procedures, systems and initiatives, and key Company policies, including the Code of Conduct.
2. Evaluate, monitor and discuss with senior management the adequacy and effectiveness of the Company's Compliance Program and compliance assurance systems and initiatives, consider recommendations for improvement thereof and provide an annual evaluation to the Board and the Compensation Committee.
3. Assist senior management, the Audit Committee and the Board of Directors in assessing financial risk arising from healthcare compliance matters.
4. Oversee investigations of any executive officer with respect to matters covered by the Compliance Program, the conduct of which may be delegated to outside legal counsel, the General Counsel, the Company's legal or compliance personnel or other advisors, as appropriate based on the particular facts and circumstances.
5. Perform any other duties as may be delegated from time to time by the Board.
6. Perform any other activities consistent with this Charter as the Compliance Committee may deem necessary and appropriate for the fulfillment of its responsibilities under this Charter or as required by applicable law or regulation.

D. Procedures and Administration

1. Meetings. The Compliance Committee shall meet at least quarterly and otherwise as often as it deems necessary in order to perform its responsibilities. The Compliance Committee may also act by unanimous written consent (which may be provided in electronic form) in lieu of a meeting. The Compliance Committee shall keep such records of its meetings as it shall deem appropriate.
2. Subcommittees. The Compliance Committee may form and delegate authority to one or more subcommittees (including a subcommittee consisting of a single member) as it deems appropriate from time to time under the circumstances.
3. Reports to Board. The Compliance Committee shall report annually and as needed to the Board.
4. Charter. At least annually, the Compliance Committee shall review and reassess the adequacy of this Charter and recommend any proposed changes to the Board for approval.
5. Independent Advisors. The Compliance Committee is authorized, without further action by the Board, to engage such independent legal and other advisors as it deems necessary or appropriate to carry out its responsibilities. Such independent advisors may be the regular advisors to the Company. The Compliance Committee is empowered, without further action by the Board, to cause the

Company to pay the compensation of such advisors as established by the Compliance Committee.

6. Investigations. The Compliance Committee shall have the authority to conduct or authorize investigations into any matters within the scope of its responsibilities as it shall deem appropriate, including the authority to request any officer, employee or advisor of the Company to meet with the Compliance Committee or any advisors engaged by the Compliance Committee.
7. Funding. The Compliance Committee is empowered, without further action by the Board, to cause the Company to pay the ordinary administrative expenses of the Compliance Committee that are necessary or appropriate in carrying out its duties.
8. Self-Evaluation. The Compliance Committee shall periodically evaluate its own performance.

Exhibit A

Scope of the Compliance Program

- Compliance with the U.S. federal and state false claims law, anti-kickback statutes, federal and state privacy laws, federal and state laws governing price reporting, other U.S. federal and state healthcare compliance laws and regulations, the Foreign Corrupt Practices Act, the U.K. Bribery Act, and to the extent applicable, similar laws and regulations outside of the United States.
- Compliance with applicable industry codes, such as the Pharmaceutical Manufacturers of America Code on Interactions with Healthcare Professionals.
- Medical affairs activities.
- Third party distributor arrangements.
- Anti-bribery and anti-corruption matters.
- Reporting of payments to Healthcare Professionals (“HCPs”) and Healthcare Organizations (“HCOs”) to government entities.
- Drug sampling programs, free drug, copayment or other patient assistance/access programs, and product support programs.
- Matters relating to relationships with Patient Organizations and Patient Assistance Organizations.
- Authorship, publication and disclosure of articles and study results, including compendia submissions.
- Promotional and non-promotional activities and materials associated with HCPs, HCOs, payors, patients, caregivers, Government Officials, and other Customers.
- Educational Grants, Investigator Sponsored Research, Charitable Contributions, Sponsorships, Exhibits, and Corporate Memberships; and
- Relationships with HCPs, HCOs, patients, payors, and other users or purchasers of Apellis’s products.